Evidence map›Paper›PMID 38164471›Full record

ArticleJournal of addiction psychiatry2023

Are We Getting High Cause the Thrill is Gone?

Kenneth Blum, Thomas Mclaughlin, Mark S Gold, Marjorie C Gondre-Lewis, Panayotis K Thanos, Igor Elman, David Baron, Abdalla Bowirrat, Debamyla Barh, Jag Khalsa and 10 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of addiction psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. PGx-BasedCurrent neuropharmacology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 4 countries.

Kenneth BlumThe Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA.
Thomas MclaughlinThe Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA.
Mark S GoldDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Marjorie C Gondre-LewisDepartment of Anatomy, Howard University College of Medicine, Washington D.C., USA.
Panayotis K ThanosBehavioral Neuropharmacology and Neuroimaging Laboratory on Addiction, Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY, USA.
Igor ElmanCambridge Health Alliance, Harvard Medical School, Cambridge, MA, USA.
David BaronCenter for Sports, Exercise, Psychiatry, Western University Health Sciences, Pomona, CA, USA.
Abdalla BowirratDepartment of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel.
Debamyla BarhCentre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur, West Bengal, India.
Jag KhalsaDivision of Therapeutics and Medical Consequences, Medical Consequences of Drug Abuse and Infections Branch, NIDA-NIH, Special Volunteer, Gaithersburg, MD, USA.
Colin HannaBehavioral Neuropharmacology and Neuroimaging Laboratory on Addiction, Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY, USA.
Nicole JafariDivision of Personalized Medicine, Cross-Cultural Research and Educational Institute, San Clemente, CA, USA.
Foojan ZeineDepartment of Health Science, California State University at Long Beach, Long Beach, CA, USA.
Eric R BravermanThe Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA.
Catherine DennenDepartment of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, USA.
Milan T MakaleDepartment of Radiation Medicine and Applied Sciences, UC San Diego, La Jolla, CA, USA.
Miles MakaleDepartment of Psychology, UC San Diego, La Jolla, CA, USA.
Keerthy SunderThe Sunder Foundation, Palm Springs, CA, USA.
Kevin T MurphyDepartment of Radiation Oncology, University of California, San Diego, La Jolla, USA.
Rajendra D BadgaiyanDepartment of Psychiatry, Case University, School of Medicine, Cleveland, OH, USA.
University of California San Diego · USJacobs Institute · USNeuroGenetic Pharmaceuticals (United States) · USAriel University · ILCambridge Health Alliance · USEötvös Loránd University · HUFrequency Therapeutics (United States) · USHealth Awareness (United States) · USHoward University · USInstitute of Bioinformatics and Applied Biotechnology · INThe Chicago School · USThomas Jefferson University Hospital · USUniversity Hospitals Cleveland Medical Center · USUniversity of California, Riverside · USWashington University in St. Louis · USWestern University of Health Sciences · US

Funding

Prenatal Tobacco and Cannabis Exposure: A Translational StudyR33DA045640 · NIDA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI EIDEN, RINA D, THANOS, PANAYOTIS K · 2021 to 2023
$999k
Prenatal Tobacco and Cannabis Exposure: A Translational StudyR21DA045640 · NIDA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI EIDEN, RINA D, THANOS, PANAYOTIS K · 2018 to 2019
$434k
A Systematic Medical Approach to Reward Transformation (SMART) for Brain Health in Opioid Use DisorderR41MD012318 · NIMHD · VERSA INTEGRATED SOLUTIONS, INC. · PI BLUM, KENNETH, GONDRE-LEWIS, MARJORIE C · 2017 to 2017
$221k
Dopamine Neurotransmission in AddictionI01CX000479 · VA · VA WESTERN NEW YORK HEALTHCARE SYSTEM · PI BADGAIYAN, RAJENDRA D · 2013 to 2014
–
CSRD VA I01 CX000479CSRD VA I01 CX002099NIDA NIH HHS R21 DA045640NIDA NIH HHS R33 DA045640NIMHD NIH HHS R41 MD012318
6 · The paper itself

Abstract

In the USA alone, opioid use disorder (OUD) affects approximately 27 million people. While the number of prescriptions may be declining due to increased CDC guidance and prescriber education, fatalities due to fentanyl-laced street heroin are still rising. Our laboratory has extended the overall concept of both substance and non-substance addictive behaviors, calling it "Reward Deficiency Syndrome (RDS)." Who are its victims, and how do we get this unwanted disorder? Is RDS caused by genes (Nature), environment (Neuro-epigenetics, Nurture), or both? Recent research identifies resting-state functional connectivity in the brain reward circuitry as a crucial factor. Analogously, it is of importance to acknowledge that the cumulative discharge of dopamine, governed by the nucleus accumbens (NAc) and modulated by an array of additional neurotransmitters, constitutes a cornerstone of an individual's overall well-being. Neuroimaging reveals that high-risk individuals exhibit a blunted response to stimuli, potentially due to DNA polymorphisms or epigenetic alterations. This discovery has given rise to the idea of a diminished 'thrill,' though we must consider whether this 'thrill' may have been absent from birth due to high-risk genetic predispositions for addiction. This article reviews this issue and suggests the general concept of the importance of "induction of dopamine homeostasis." We suggest coupling a validated genetic assessment (e.g., GARS) with pro-dopamine regulation (KB220) as one possible frontline modality in place of prescribing potent addictive opioids for OUD except for short time harm reduction. Could gene editing offer a 'cure' for this undesirable genetic modification at birth, influenced by the environment and carried over generations, leading to impaired dopamine and other neurotransmitter imbalances, as seen in RDS? Through dedicated global scientific exploration, we hope for a future where individuals are liberated from pain and disease, achieving an optimal state of well-being akin to the proverbial 'Garden of Eden'.

Indexed as

DopamineFunctional connectivityGenetic addiction risk severityNeurotransmittersPro-dopamine regulationReward brain circuitryThrill is gone

Identifiers

PMID38164471
PMCPMC10758019
OpenAlexW4390507686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.